Market Overview

UPDATE: JP Morgan Raises PT on Pfizer on Takeaways from Meeting with Management

Share:
Related PFE
PreMarket Prep Recap, March 21: We Haven't Seen A 2% Correction Since The Election
Anatomy Of A Decision, Part 1: The C-Suite
Fifth Portfolio Review - 'The Accelerated Dividend Portfolio' (Seeking Alpha)

JP Morgan maintained Pfizer (NYSE: PFE) with an Overweight rating and raised the price target from $31.00 to $32.00.

JP Morgan analyst Chris Schott commented, "Overall, we see several interesting assets in Pfizer's pipeline beyond Eliquis and Xeljanz (most notably PD-991) and believe we are beginning to see results from the company's refocused R&D efforts. In addition, we continue to believe that a larger break-up of Pfizer remains a distinct possibility, particularly if the company's core pharmaceutical portfolio is able to generate sustained growth over time."

Pfizer closed at $27.99 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Dec 2016GuggenheimInitiates Coverage OnNeutral
Nov 2016BarclaysUpgradesEqual-WeightOverweight
Nov 2016BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!